Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

BACKGROUND: Results from the recent CROSS trial showed that neoadjuvant chemoradiotherapy (nCRT) significantly increased survival as compared to surgery alone in patients with potentially curable esophageal cancer. Furthermore, in the nCRT arm 49% of patients with a squamous cell carcinoma (SCC) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Noordman, Bo Jan, Shapiro, Joel, Spaander, Manon CW, Krishnadath, Kausilia K, van Laarhoven, Hanneke WM, van Berge Henegouwen, Mark I, Nieuwenhuijzen, Grard AP, van Hillegersberg, Richard, Sosef, Meindert N, Steyerberg, Ewout W, Wijnhoven, Bas PL, van Lanschot, J Jan B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications Inc. 2015
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526968/
https://www.ncbi.nlm.nih.gov/pubmed/26121676
http://dx.doi.org/10.2196/resprot.4320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526968/
https://www.ncbi.nlm.nih.gov/pubmed/26121676
http://dx.doi.org/10.2196/resprot.4320

Ejemplares similares